# Phase 2 Neoplasm Metastasis trials recruiting: 118 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 118 trials in phase 2 for Neoplasm Metastasis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Neoplasm Metastasis trials: 118 rows for $5.90, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/neoplasm-metastasis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 118
- Recruiting or not yet: 118
- Read on: November 19, 2026

## Trials

The 25 newest of 118, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07942064 | Remote Exercise iNtErvention for Wellbeing (RENEW) Trial | University of British Columbia | Phase 2 | Not yet recruiting | Exercise Adherence (Primary), Depressive Symptoms (Secondary), Anxiety (Secondary), Presenteeism Secondary), Wellbeing... | 664 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07942064) |
| November 13, 2026 | NCT07935226 | Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBC | Harbin Medical University | Phase 2 | Not yet recruiting | Breast Cancer (Locally Advanced or Metastatic), HR Positive/HER2 Low Breast Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935226) |
| November 10, 2026 | NCT07928167 | Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients | Kidney Cancer Research Bureau | Phase 2 | Recruiting | Metastatic Renal Cell Carcinoma ( mRCC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928167) |
| October 29, 2026 | NCT07905313 | Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and... | Azienda Ospedaliero-Universitaria Careggi | Phase 2 | Not yet recruiting | Breast Cancer (Advanced/Metastatic) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905313) |
| October 28, 2026 | NCT07901803 | Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma | Washington University School of Medicine | Phase 2 | Not yet recruiting | Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901803) |
| October 6, 2026 | NCT07859592 | Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma | VA Office of Research and Development | Phase 2 | Not yet recruiting | Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859592) |
| October 5, 2026 | NCT07856914 | Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma, Peritoneal Carcinosis, Peritoneal Cancer, Peritoneal... | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856914) |
| September 28, 2026 | NCT07844057 | First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Small-bowel Adenocarcinoma, Metastatic Disease, Chemotherapy Effect | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844057) |
| September 17, 2026 | NCT07824856 | Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases, Oligometastatic Disease, Ablation... | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824856) |
| August 28, 2026 | NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Not yet recruiting | Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793253) |
| August 21, 2026 | NCT07780578 | The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Fudan University | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780578) |
| August 4, 2026 | NCT07743554 | Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | MPNST (Malignant Peripheral Nerve Sheath Tumor) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743554) |
| July 23, 2026 | NCT07722754 | Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial | Guangdong Provincial People's Hospital | Phase 2 | Recruiting | Colorectal Neoplasms Malignant, Neoplasm, Metastatic | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722754) |
| July 6, 2026 | NCT07684040 | A Study of Combination Therapy in Patients With Resectable Liver Cancer | Affiliated Hospital of Guangdong Medical University | Phase 2 | Not yet recruiting | Liver Cancer (Primary and Metastatic) | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684040) |
| July 6, 2026 | NCT07682675 | Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck | UNICANCER | Phase 2 | Not yet recruiting | Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence, Metastatic Disease | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682675) |
| July 2, 2026 | NCT07680205 | An Experimental Study of Belzutifan Impact on Catecholamine Metabolism | Cambridge University Hospitals NHS Foundation Trust | Phase 2 | Recruiting | Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680205) |
| June 29, 2026 | NCT07672782 | Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | GOG Foundation | Phase 2 | Not yet recruiting | Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672782) |
| June 22, 2026 | NCT07659678 | CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma | Washington University School of Medicine | Phase 2 | Recruiting | Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659678) |
| June 18, 2026 | NCT07658183 | A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone... | Shanghai Best-Link Bioscience, LLC | Phase 2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658183) |
| June 9, 2026 | NCT07635524 | A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT. | Hoag Memorial Hospital Presbyterian | Phase 2 | Not yet recruiting | Prostate Cancer | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635524) |
| June 8, 2026 | NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631884) |
| May 27, 2026 | NCT07608029 | Xiaochaihu Granules for Depression After Allogeneic Hematopoietic Stem Cell Transplantation | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Depressive Disorder, Secondary, Hematopoietic Stem Cell Transplantation | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608029) |
| May 18, 2026 | NCT07594431 | Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases. | Stanford University | Phase 2 | Recruiting | Metastases, Metastatic Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594431) |
| May 12, 2026 | NCT07581821 | Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Recurrent or Metastatic Nasopharyngeal Carcinoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581821) |
| May 8, 2026 | NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576725) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| UNICANCER | 7 |
| M.D. Anderson Cancer Center | 6 |
| National Cancer Institute (NCI) | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Fudan University | 3 |
| Sun Yat-sen University | 3 |
| Gustave Roussy, Cancer Campus, Grand Paris | 2 |
| University of California, San Diego | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| Dartmouth-Hitchcock Medical Center | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| Centre Leon Berard | 2 |
| Washington University School of Medicine | 2 |
| Hackensack Meridian Health | 1 |
| University of Vermont Medical Center | 1 |
| University of Sao Paulo | 1 |
| Buzzard Pharmaceuticals | 1 |
| University of Wisconsin, Madison | 1 |
| QBiotics Group Limited | 1 |
| Roswell Park Cancer Institute | 1 |
| GOG Foundation | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| ALX Oncology Inc. | 1 |
| Riboscience, LLC. | 1 |
| Grupo Español Multidisciplinar de Melanoma | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 54 |
| China | 20 |
| France | 15 |
| Spain | 5 |
| Germany | 5 |
| Italy | 4 |
| Canada | 3 |
| South Korea | 3 |
| Denmark | 2 |
| Singapore | 2 |
| United Kingdom | 2 |
| Puerto Rico | 2 |
| Japan | 2 |
| Netherlands | 2 |
| Russia | 2 |
| Brazil | 1 |
| Vietnam | 1 |
| Egypt | 1 |
| Slovenia | 1 |
| Uganda | 1 |
| Malaysia | 1 |
| Austria | 1 |
| Belgium | 1 |
| Australia | 1 |
| Poland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pest control companies in the United States](https://specstream.ai/data/businesses/pest-control-companies/united-states)
- [Elevator companies in the United States](https://specstream.ai/data/businesses/elevator-companies/united-states)
- [Uzbek restaurants in the United States](https://specstream.ai/data/businesses/uzbek-restaurants/united-states)
- [Lebanese restaurants in the United States](https://specstream.ai/data/businesses/lebanese-restaurants/united-states)
- [Cambodian restaurants in the United States](https://specstream.ai/data/businesses/cambodian-restaurants/united-states)
- [Retaining wall suppliers in the United States](https://specstream.ai/data/businesses/retaining-wall-suppliers/united-states)
